Chemed reports Q2 EPS $5.64 vs. $4.93 last year
The Fly

Chemed reports Q2 EPS $5.64 vs. $4.93 last year

Reports Q2 revenue $606.2M vs. $564.5M last year. VITAS segment operating results: Net Patient Revenue of $391.4 million, an increase of 17.3%, Average Daily Census (ADC) of 21,785, an increase of 15.5%, Admissions of 16,775, an increase of 6.3%. Roto-Rooter segment operating results: Revenue of $214.8 million, a decrease of 6.9%.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App